Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
NEW YORK–Merkley Newman Harty Healthworks has landed ad duties on a new arthritis drug that Novartis plans to bring to market in 2004, the agency confirmed.
Billings have not been determined, but the new drug, a Cox-2 inhibitor that has yet to be named, will compete with Vioxx, which spent $135 million last year, and Celebrex, which spent $130 million, according to CMR.
Novartis’ selection came after a review that also included Ogilvy & Mather, Bates Healthworld and McCann-Erickson.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in